AstraZeneca
oncology highlights novel programmes advance with new pivotal trials including in accelerated development in sensitive types longer follow up data for dose supports transition to late stage phase first patient dosed in five phase planned in across key types including current soc regimens new phase planned to initiate in expanded phase in development | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
20 of 45
Related slides by other companies
Compass Therapeutics
Investor Presentation
May 2023
development status enabling activities phase study planning see tin doses planned and compass | Compass Therapeutics
Alkermes
Investor Presentation
January 2023
clinical development plan designed to rapidly advance program in | Alkermes
Alkermes
Investor Presentation
March 2023
clinical development plan designed to rapidly advance program in | Alkermes
Nuvalent
Investor Presentation
January 2024
for her a brain penetrant her selective inhibitor with to minimize related adverse events activity against mutations and the potential i | Nuvalent
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io